Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

ABSTRACT: Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies¹. Tumor complexity and heterogeneity suggest that the 'precision medicine' paradigm of cancer therapy requires treatment to be personalized to the individual patient^2-6. To date, precision oncology trials have been based on molecular matching with predetermined monotherapies^7-14. Several of these trials have been hindered by very low matching rates, often in the 5-10% range¹⁵, and low response rates. Low matching rates may be due to the use of limited gene panels, restrictive molecular matching algorithms, lack of drug availability, or the deterioration and death of end-stage pa

SUBMITTER: Sicklick JK 

PROVIDER: S-EPMC6553618 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature